Mine K, Okada M, Mishima N, Fujiwara M, Nakagawa T
Department of Psychosomatic Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Biol Psychiatry. 1993 Nov 1;34(9):654-60. doi: 10.1016/0006-3223(93)90159-b.
The plasma levels of free and sulfoconjugated forms of 3-methoxy-4-hydroxyphenylglycol (MHPG) were examined before and after treatment in 16 patients with unipolar major depressive disorders without melancholia. The patients were treated with intravenous administration of clomipramine for 4 weeks. Seven depressive disorder patients who showed marked improvement (the improvement group) revealed significant reduction in their plasma sulfoconjugated MHPG levels. In 6 depressive disorder patients who showed no improvement (the no-improvement group), the plasma sulfoconjugated MHPG levels showed no significant change after treatment. The remaining 3 patients, who showed ambiguous change after treatment, were excluded from the analysis. Levels of plasma-free MHPG showed significant change after treatment in neither the improvement group nor in the no-improvement group. It is suggested that levels of plasma sulfoconjugated MHPG may serve as an indicator of brain noradrenergic activity.
在16例无忧郁症的单相重度抑郁症患者中，检测了治疗前后3-甲氧基-4-羟基苯乙二醇（MHPG）游离形式和硫酸结合形式的血浆水平。患者接受氯米帕明静脉注射治疗4周。7例显示明显改善的抑郁症患者（改善组）血浆硫酸结合型MHPG水平显著降低。6例无改善的抑郁症患者（无改善组）治疗后血浆硫酸结合型MHPG水平无显著变化。其余3例治疗后变化不明确的患者被排除在分析之外。改善组和无改善组治疗后血浆游离型MHPG水平均无显著变化。提示血浆硫酸结合型MHPG水平可能作为脑去甲肾上腺素能活性的指标。
